Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18899

+
MS 07 - Neuroendocrine Tumors other than SCLC: Pathology to Patient Management
- 15:45 - 17:30
- 10/16/2017
- Location: F203 + F204 (Annex Hall)
- Type: Mini Symposium
- Track: SCLC/Neuroendocrine Tumors
- Moderators:C. Barrios, Sang-We Kim
- 23013
  
  +
  
  MS 07.05 - ESTS Registration for Neuroendocrine Tumors
  
  16:45 - 17:00 | Presenter: Pier Luigi Filosso | Author(s): F. Guerrera, P. Lyberis, E.L.N.S. Committee
  Abstract
  
  Loading...
20170

+
P2.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- 23365
  
  +
  
  P2.06-001 - Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)
  
  09:30 - 09:30 | Presenter: Tricia L. Larose | Author(s): F. Guida, P. Brennan, M. Johansson
  Abstract
  
  Loading...
20183

+
P3.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- 24089
  
  +
  
  P3.04-013 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
  
  09:30 - 09:30 | Presenter: Pasi A Jänne | Author(s): H.A. Yu, M. Vigliotti, N. Shipitofsky, J. Singh, F. Guevara, C. Yu
  Abstract
  
  Loading...
20196

+
P3.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- 24279
  
  +
  
  P3.17-003 - A Selective Small Molecule Inhibitor of C-Met Kinase, BPI-9016M, Has Synergistic Effects with Radiation on Esophageal Squamous Cell Carcinoma
  
  09:30 - 09:30 | Presenter: Yaping Xu | Author(s): C. Jiang, S. Han, G. Lin, F. Gu, Q. Lin, J. Feng
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

MS 07 - Neuroendocrine Tumors other than SCLC: Pathology to Patient Management

+

MS 07.05 - ESTS Registration for Neuroendocrine Tumors

+

P2.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation

+

P2.06-001 - Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)

+

P3.04 - Clinical Design, Statistics and Clinical Trials

+

P3.04-013 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

+

P3.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

+

P3.17-003 - A Selective Small Molecule Inhibitor of C-Met Kinase, BPI-9016M, Has Synergistic Effects with Radiation on Esophageal Squamous Cell Carcinoma

Stay Connected